Liverpool HIV Interactions

Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

No Interaction Expected

Rilpivirine/ Emtricitabine/Tenofovir-DF (RPV/FTC/TDF)

Sildenafil (Erectile Dysfunction)

Quality of Evidence: Very Low

Summary:

Coadministration with Eviplera/Complera has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of rilpivirine (75 mg once daily) and sildenafil (50 mg single dose) decreased rilpivirine Cmax and AUC by 8% and 2%, and increased Cmin by 4%. Sildenafil Cmax and AUC decreased by 7% and 3%; N-desmethyl sildenafil Cmax and AUC decreased by 10% and 8%, respectively. [Note: this interaction study has been performed with a dose higher than the licensed dose for rilpivirine assessing the maximal effect on the co-administered drug]. Emtricitabine and tenofovir-DF do not interact with sildenafil.

Description:

The interaction between sildenafil and emtricitabine or tenofovir disoproxil had not been studied. Coadministration of sildenafil (50 mg single dose) and rilpivirine had no effect on sildenafil AUC or Cmax and there was no change in AUC, Cmin or Cmax of rilpivirine. No dose adjustment is required. (This interaction study has been performed with a dose higher than the recommended dose for rilpivirine hydrochloride assessing the maximal effect on the co-administered medicinal product. The dosing recommendation is applicable to the recommended dose of rilpivirine of 25 mg once daily.)

Eviplera Summary of Product Information, Gilead Sciences Ltd, August 2021.

No clinically significant drug interactions have been observed between RPV and sildenafil. Coadministration of sildenafil (50 mg single dose) and rilpivirine (75 mg once daily) was studied in 16 subjects. Rilpivirine Cmax and AUC decreased by 8% and 2%, but Cmin increased by 4%. Sildenafil Cmax and AUC decreased by 7% and 3%; N-desmethyl-sildenafil decreased by 10% and 8%.

Complera US Prescribing Information, Gilead Sciences Inc, November 2019.

Coadministration of rilpivirine (75 mg once daily) and sildenafil (50 mg single dose) was studied in 16 subjects. Rilpivirine Cmax and AUC decreased by 8% and 2%, respectively, and Cmin increased by 4%. Sildenafil Cmax and AUC decreased by 7% and 3%, respectively; N-desmethyl sildenafil Cmax and AUC decreased by 10% and 8%, respectively.

Crauwels HM, et al. TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor, does not alter the pharmacokinetics of sildenafil. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract P22.

View all available interactions with Rilpivirine/ Emtricitabine/Tenofovir-DF (RPV/FTC/TDF) by clicking here.